We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
-0.1%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$2.83B
AUM Growth
-$798M
Cap. Flow
-$482M
Cap. Flow %
-17.04%
Top 10 Hldgs %
54.55%
Holding
115
New
16
Increased
15
Reduced
28
Closed
28

Top Buys

Rank Stock Value
1
EWTX icon
Edgewise Therapeutics
EWTX
+$101M
2
BBNX
Beta Bionics
BBNX
+$29.7M
3
INSM icon
Insmed
INSM
+$27.9M
4
DYN icon
Dyne Therapeutics
DYN
+$25.3M
5
SLDB icon
Solid Biosciences
SLDB
+$21.4M

Top Sells

Rank Stock Value
1
PCVX icon
Vaxcyte
PCVX
+$80.9M
2
NUVL
Nuvalent
NUVL
+$77.1M
3
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$62.8M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$62.6M
5
CNTA
Centessa Pharmaceuticals
CNTA
+$54.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRNA
1
DELISTED
Verona Pharma
VRNA
$417M 14.72%
6,563,340
+171,234
+3% +$10.2M
ACLX
2
DELISTED
Arcellx
ACLX
$192M 6.78%
2,926,478
-552,410
-16% -$37.4M
FOLD
3
DELISTED
Amicus Therapeutics
FOLD
$175M 6.19%
21,464,527
-2,781,425
-11% -$25.7M
EWTX icon
4
Edgewise Therapeutics
EWTX
$4.32B
$144M 5.09%
6,547,328
+3,861,791
+144% +$101M
RYTM icon
5
Rhythm Pharmaceuticals
RYTM
$7.36B
$135M 4.77%
2,548,445
-1,132,028
-31% -$62.8M
NUVL
6
DELISTED
Nuvalent
NUVL
$116M 4.09%
1,633,968
-986,009
-38% -$77.1M
SLNO
7
DELISTED
Soleno Therapeutics
SLNO
$108M 3.8%
1,506,602
+5,562
+0.4% +$271K
ITCI
8
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$104M 3.66%
786,358
-501,970
-39% -$62.6M
MGTX icon
9
MeiraGTx Holdings
MGTX
$1.07B
$85.3M 3.01%
12,581,103
– –
AORT icon
10
Artivion
AORT
$1.34B
$68.7M 2.43%
2,793,703
– –
ALDX icon
11
Aldeyra Therapeutics
ALDX
$92.9M
$53.3M 1.88%
9,275,851
– –
PTGX icon
12
Protagonist Therapeutics
PTGX
$8.74B
$52.8M 1.86%
1,091,271
-180,391
-14% -$7.56M
EOLS icon
13
Evolus
EOLS
$398M
$49.7M 1.75%
4,129,142
-1,016,704
-20% -$13.3M
IMVT icon
14
Immunovant
IMVT
$7.96B
$48.6M 1.72%
2,844,072
+704,873
+33% +$14.7M
SLDB icon
15
Solid Biosciences
SLDB
$783M
$44.1M 1.56%
11,906,646
+5,000,000
+72% +$21.4M
CNTA
16
DELISTED
Centessa Pharmaceuticals
CNTA
$43.7M 1.54%
3,040,395
-3,308,825
-52% -$54.1M
IOVA icon
17
Iovance Biotherapeutics
IOVA
$2.04B
$42.3M 1.5%
12,711,788
-9,400,478
-43% -$48.5M
IMTX icon
18
Immatics
IMTX
$1.18B
$42.3M 1.5%
9,383,456
– –
APGE icon
19
Apogee Therapeutics
APGE
$10.1B
$41.9M 1.48%
1,122,767
+75,535
+7% +$2.92M
AXSM icon
20
Axsome Therapeutics
AXSM
$11.9B
$41.4M 1.46%
355,107
-308,967
-47% -$35.2M
INSM icon
21
Insmed
INSM
$22.7B
$38.9M 1.37%
509,300
+365,300
+254% +$27.9M
SYRE icon
22
Spyre Therapeutics
SYRE
$8.46B
$37.3M 1.32%
2,313,272
-261,451
-10% -$5.44M
PRAX icon
23
Praxis Precision Medicines
PRAX
$8.18B
$37.1M 1.31%
980,894
-348,841
-26% -$21.8M
ARGX icon
24
argenx
ARGX
$55.2B
$35.2M 1.24%
59,510
-7,961
-12% -$5.02M
ATXS
25
DELISTED
Astria Therapeutics
ATXS
$34.6M 1.22%
6,485,420
– –
1
2 3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q1 2025 Portfolio in Review

As of Q1 2025, Perceptive Advisors held 115 positions worth $2.83B, down 22% from $3.63B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Perceptive Advisors withdrew a net $482M in Q1 2025, closing 28 positions and reducing 28 holdings. Its most notable exit was Procept Biorobotics, an estimated $23.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

Against the trend, Perceptive Advisors opened a new position in Beta Bionics worth $19.5M.

  • Perceptive Advisors's largest Q1 2025 buy was Beta Bionics: 1,593,608 shares worth $19.5M.
  • Perceptive Advisors added most to Edgewise Therapeutics in Q1 2025, an estimated $101M increase.
  • Perceptive Advisors's biggest Q1 2025 reduction was Vaxcyte, cutting an estimated $80.9M.
  • Perceptive Advisors fully exited Procept Biorobotics in Q1 2025, selling an estimated $23.4M.
  • Perceptive Advisors's ten largest holdings make up 55% of its $2.83B portfolio in Q1 2025.
  • Perceptive Advisors opened 16 new positions and closed 28 in Q1 2025.
  • Perceptive Advisors's portfolio value fell 22% quarter-over-quarter to $2.83B.

Based on Perceptive Advisors's 13F filing for Q1 2025, filed 15 May 2025.